| PR Title: |
Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer; potential to address significant unmet need |
| PR Summary: |
Novartis announced today that an interim analysis of a pivotal Phase III study showed Afinitor® (everolimus) tablets in combination with exemestane significantly extended progression-free survival (PFS), or time without tumor growth, when compared to placebo plus exemestane in women with advanced breast cancer. |